ClinicalTrials.gg
CompletedNCT01514448Updated Jul 19, 2017Results posted

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

A Phase 4 interventional study of Everolimus (RAD001) in Metastatic Renal Cell Carcinoma (mRCC), sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing everolimus in Carcinoma, Renal Cell — 4 open to participants now, 7 under way, 2 of them phase 3. Everolimus · Carcinoma, Renal Cell.

Enrollment
33rd of 48
29 · median 46
Started
2012
with 3 others
Phase 4
5 of 48
none open now
Registered
31st of 48
by date
Lead sponsor
9 of 48
Novartis Pharmaceuticals

Among the 48 studies testing everolimus in Carcinoma, Renal Cell, this one is the 33rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 4, and was the 31st registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

4 of the 48 studies testing everolimus in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing everolimus in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.

03

Conditions studied

  • Metastatic Renal Cell Carcinoma (mRCC)

Keywords

  • Kidney cancer
  • mRCC
  • metastic renal cell carcinoma
  • everolimus
  • sunitinib
  • pazopanib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
  • Progression during or after a treatment with sunitinib or pazopanib given in a treatment situation for mRCC.
  • Patients scheduled for treatment with everolimus.
  • Patients with at least one at baseline as per v1.1.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received >1 prior systemic treatment for their RCC. Prior systemic treatment in an setting is allowed.
  • Patients who have previously received systemic mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus).
  • Patients who are using other agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
  • Patients unwilling or unable to comply with the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Everolimus

    Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.

    Drug: Everolimus (RAD001)

Interventions

  • Everolimus was used as commercially available formulated tablets of 10 mg strength

    Also known as: RAD001

06

What researchers measure

Primary outcomes

  1. Percentage of Progression-free Patients by Month 6

    Percentage of progression-free patients by month 6 after starting everolimus treatment. For the purpose of the binomial design of the study, a patient being 'progression-free' will be defined as a patient without disease progression by month 6 whereas a subject with progressive disease by month 6 will not be counted as 'progression-free'. The primary variable was derived from radiologic tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) Disease progression was either 1) a 20% increase in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameters of all target lesions recorded at or after baseline (minimum absolute increase 5 mm in sum) or 2) the appearance of a new lesion or 3) the unequivocal progression of non-target lesions overall.

    Time frame: Month 6

Secondary outcomes

  1. Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6

    Overall response rate (ORR) is the Percentage of patients with a best overall response of complete response (CR) or partial response (PR) by month 6. ORR was assessed according to RECIST 1.1 criteria. Partial response (PR) required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as reference the baseline sum of the longest diameters. Complete response (CR) required a disappearance of all target and non-target lesions.

    Time frame: Month 6

  2. Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months

    Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient did not have an event, progression-free survival was censored at the date of last adequate tumor assessment

    Time frame: 24 months

  3. Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months

    Overall survival (OS) was defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival will be censored at the date of last contact.

    Time frame: 48 months

  4. Duration of Response (DOR) in Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months

    The duration of overall response (DOR) was defined as the time from the first occurrence of a confirmed Complete Response (CR) or Partial Response (PR) (as per investigator assessment according to RECIST 1.1) until the date of the first documented disease progression or death due to underlying cancer. If a patient did not have an event or received any further anticancer therapy, duration of overall response was censored at the date of last adequate tumor assessment. Duration of response was displayed only for patients whose best overall response was CR or PR. As none of the patients showed any response (CR or PR), DOR could not be calculated

    Time frame: 48 months

07

Results

Posted Jul 19, 2017

Participant flow

Participant flow — Overall Study
Milestone1st Line SUN1st Line PAZ
Started1613
Full analysis set (fas)1213
Completed45
Not completed128
Withdrew: Death78
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up20
Withdrew: New cancer therapy10

Outcome measures

PrimaryPercentage of Progression-free Patients by Month 6

Percentage of progression-free patients by month 6 after starting everolimus treatment. For the purpose of the binomial design of the study, a patient being 'progression-free' will be defined as a patient without disease progression by month 6 whereas a subject with progressive disease by month 6 will not be counted as 'progression-free'. The primary variable was derived from radiologic tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) Disease progression was either 1) a 20% increase in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameters of all target lesions recorded at or after baseline (minimum absolute increase 5 mm in sum) or 2) the appearance of a new lesion or 3) the unequivocal progression of non-target lesions overall.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Progression-free Patients by Month 6
Percentage of participants1st Line SUN1st Line PAZ
Percentage of Progression-free Patients by Month 68.346.2
SecondaryPercentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6

Overall response rate (ORR) is the Percentage of patients with a best overall response of complete response (CR) or partial response (PR) by month 6. ORR was assessed according to RECIST 1.1 criteria. Partial response (PR) required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as reference the baseline sum of the longest diameters. Complete response (CR) required a disappearance of all target and non-target lesions.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6
percentage of participants1st Line SUN1st Line PAZ
Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 60.00.0
SecondaryProgression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months

Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient did not have an event, progression-free survival was censored at the date of last adequate tumor assessment

Time frame:
24 months
Reported as:
Median · months
Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months
months1st Line SUN1st Line PAZ
Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months2.8 (2.6 to 3.1)8.0 (3.0 to 10.3)
SecondaryOverall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months

Overall survival (OS) was defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival will be censored at the date of last contact.

Time frame:
48 months
Reported as:
Median · months
Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months
months1st Line SUN1st Line PAZ
Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months14.8 (10.0 to NA)20.4 (13.6 to NA)
SecondaryDuration of Response (DOR) in Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months

The duration of overall response (DOR) was defined as the time from the first occurrence of a confirmed Complete Response (CR) or Partial Response (PR) (as per investigator assessment according to RECIST 1.1) until the date of the first documented disease progression or death due to underlying cancer. If a patient did not have an event or received any further anticancer therapy, duration of overall response was censored at the date of last adequate tumor assessment. Duration of response was displayed only for patients whose best overall response was CR or PR. As none of the patients showed any response (CR or PR), DOR could not be calculated

Time frame:
48 months

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1st Line SUN—6/16 (37.5%)15/16 (93.8%)
1st Line PAZ—8/13 (61.5%)13/13 (100%)
Everolimus All Patients—14/29 (48.3%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
Event1st Line SUN1st Line PAZEverolimus All Patients
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders1/163/134/29
DYSPNOEARespiratory, thoracic and mediastinal disorders0/162/132/29
ANAEMIABlood and lymphatic system disorders1/161/132/29
ATRIOVENTRICULAR BLOCK COMPLETECardiac disorders0/161/131/29
ABDOMINAL PAINGastrointestinal disorders0/161/131/29
HAEMORRHOIDSGastrointestinal disorders0/161/131/29
STOMATITISGastrointestinal disorders0/161/131/29
ASTHENIAGeneral disorders0/161/131/29
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders1/161/132/29
ENDOCARDITISInfections and infestations1/161/132/29
Most frequent other events
Showing 10 of 131
Most frequent other events
Event1st Line SUN1st Line PAZEverolimus All Patients
ANAEMIABlood and lymphatic system disorders4/167/1311/29
STOMATITISGastrointestinal disorders2/167/139/29
FATIGUEGeneral disorders5/167/1312/29
OEDEMA PERIPHERALGeneral disorders2/167/139/29
NAUSEAGastrointestinal disorders3/166/139/29
DECREASED APPETITEMetabolism and nutrition disorders5/165/1310/29
COUGHRespiratory, thoracic and mediastinal disorders6/165/1311/29
DYSPNOEARespiratory, thoracic and mediastinal disorders2/165/137/29
EPISTAXISRespiratory, thoracic and mediastinal disorders2/165/137/29
PRURITUSSkin and subcutaneous tissue disorders3/165/138/29

Baseline characteristics

Demographic and other baseline data (including disease characteristics) were summarized descriptively for all patients for the FAS. The full analysis set (FAS) consisted of all patients who received at least one dose of everolimus.

Age, Continuous
Age, Continuous(years)1st Line SUN1st Line PAZTotal
Mean67.6 ± 6.371.3 ± 6.069.2 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)1st Line SUN1st Line PAZTotal
Female628
Male61117
08

Study locations

13 sites
  • Novartis Investigative Site
    Chemnitz, 09130, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Hannover, 30559, Germany
  • Novartis Investigative Site
    Hof, 95028, Germany
  • Novartis Investigative Site
    Kassel, 34125, Germany
  • Novartis Investigative Site
    Langen, 63225, Germany
  • Novartis Investigative Site
    Leipzig, 04357, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Ravensburg, 88214, Germany
  • Novartis Investigative Site
    Velbert, 42551, Germany
  • Novartis Investigative Site
    Wiesbaden, 65191, Germany
  • Novartis Investigative Site
    Wolfsburg, 38440, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2012 to primary completion in Apr 2016, 46 months.

Results were first posted in Jul 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2012
First posted
Jan 23, 2012
StartActual
May 21, 2012
Primary completionActual
Apr 1, 2016
CompletionActual
Apr 1, 2016
Results first posted
Jul 19, 2017
Last update
Jul 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01514448
Responsible party
Sponsor
First posted
Jan 23, 2012
Start date
May 21, 2012
Primary completion
Apr 1, 2016
Completion
Apr 1, 2016
Results posted
Jul 19, 2017
Last update
Jul 19, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion